- ISRG has 17x the normal benchmarked social activity for this time of the day compared to its average of 15.94 mentions/day.
- ISRG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $241.8 million.
Identifying stocks with 'Unusual Social Activity' tends to be a valuable process for traders looking to capitalize on the 'talk of the town' stocks that are basking in far more attention from the StockTwits financial community than normal. Good press? Bad press? It ultimately doesn't matter if it's good or bad if you know how to trade around the sentiment. Certain hedge funds use such data for their proprietary algorithms and it is not uncommon to see shared social sentiment play itself out in a stock's price trend. EXCLUSIVE OFFER: Get the inside scoop on opportunities in ISRG with the Ticky from Trade-Ideas. See the FREE profile for ISRG NOW at Trade-Ideas More details on ISRG: Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. ISRG has a PE ratio of 29.2. Currently there are 8 analysts that rate Intuitive Surgical a buy, 3 analysts rate it a sell, and 7 rate it a hold. The average volume for Intuitive Surgical has been 523,800 shares per day over the past 30 days. Intuitive Surgical has a market cap of $14.6 billion and is part of the health care sector and health services industry. The stock has a beta of 0.69 and a short float of 8.9% with 5.33 days to cover. Shares are up 2.1% year-to-date as of the close of trading on Tuesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Intuitive Surgical as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and weak operating cash flow. Highlights from the ratings report include:
- ISRG has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 3.91, which clearly demonstrates the ability to cover short-term cash needs.
- The gross profit margin for INTUITIVE SURGICAL INC is currently very high, coming in at 71.53%. Regardless of ISRG's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 9.53% trails the industry average.
- ISRG, with its decline in revenue, underperformed when compared the industry average of 6.0%. Since the same quarter one year prior, revenues fell by 24.0%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 76.5% when compared to the same quarter one year ago, falling from $188.90 million to $44.30 million.
- The share price of INTUITIVE SURGICAL INC has not done very well: it is down 8.02% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. Looking ahead, we do not see anything in this company's numbers that would change the one-year trend. It was down over the last twelve months; and it could be down again in the next twelve. Naturally, a bull or bear market could sway the movement of this stock.
- You can view the full Intuitive Surgical Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.